Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia
Clinical Infectious Diseases2010Vol. 51(12), pp. 1395–1405
Citations Over TimeTop 1% of 2010 papers
Thomas M. File, Donald E. Low, Paul B. Eckburg, George H. Talbot, H. David Friedland, Jon Lee, Lily Llorens, Ian A. Critchley, Dirk Thye
Abstract
Ceftaroline was noninferior to ceftriaxone in the individual trials. In this integrated analysis, clinical cure rates for the ceftaroline group were numerically higher than those for the ceftriaxone group. Ceftaroline was well tolerated, with a safety profile similar to that of ceftriaxone.
Related Papers
- → Cost-Effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany(1999)18 cited
- → Ceftriaxone: A Beta‐lactamase—stable, Broad‐spectrum Cephalosporin with an Extended Half‐life(1985)34 cited
- → No evidence of reduced cephalosporin susceptibility of circulating strains ofNeisseria gonorrhoeaein the Netherlands despite nearly a decade of recommending ceftriaxone monotherapy(2022)2 cited
- → PHV13: COST ANALYSIS OF CEFTRIAXONE VERSUS CEFTRIAXONE PLUS MACROLIDE TREATMENT FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)(2000)
- [Clinical study of a new cephalosporin, ceftriaxone (Rocefin Roche) in bronchopneumonia in children].(1984)